Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases. / Harboe, Zitta Barrella; Hamm, Sebastian Rask; Pérez-Alós, Laura; Sivapalan, Pradeesh; Priemé, Helene; Wilcke, Torgny; Kjeldgaard, Peter; Shaker, Saher; Svorre Jordan, Alexander; Møller, Dina Leth; Heftdal, Line Dam; Madsen, Johannes Roth; Bayarri-Olmos, Rafael; Hansen, Cecilie Bo; Pries-Heje, Mia Marie; Hasselbalch, Rasmus Bo; Fogh, Kamille; Armenteros, Jose Juan Almagro; Hilsted, Linda; Sørensen, Erik; Lindegaard, Birgitte; Browatzki, Andrea; Biering-Sørensen, Tor; Frikke-Schmidt, Ruth; Ostrowski, Sisse Rye; Iversen, Kasper Karmark; Bundgaard, Henning; Nielsen, Susanne Dam; Garred, Peter; Jensen, Jens-Ulrik Stæhr.

I: BMJ Open Respiratory Research, Bind 9, Nr. 1, 2022.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Harboe, ZB, Hamm, SR, Pérez-Alós, L, Sivapalan, P, Priemé, H, Wilcke, T, Kjeldgaard, P, Shaker, S, Svorre Jordan, A, Møller, DL, Heftdal, LD, Madsen, JR, Bayarri-Olmos, R, Hansen, CB, Pries-Heje, MM, Hasselbalch, RB, Fogh, K, Armenteros, JJA, Hilsted, L, Sørensen, E, Lindegaard, B, Browatzki, A, Biering-Sørensen, T, Frikke-Schmidt, R, Ostrowski, SR, Iversen, KK, Bundgaard, H, Nielsen, SD, Garred, P & Jensen, J-US 2022, 'Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases', BMJ Open Respiratory Research, bind 9, nr. 1. https://doi.org/10.1136/bmjresp-2022-001268

APA

Harboe, Z. B., Hamm, S. R., Pérez-Alós, L., Sivapalan, P., Priemé, H., Wilcke, T., Kjeldgaard, P., Shaker, S., Svorre Jordan, A., Møller, D. L., Heftdal, L. D., Madsen, J. R., Bayarri-Olmos, R., Hansen, C. B., Pries-Heje, M. M., Hasselbalch, R. B., Fogh, K., Armenteros, J. J. A., Hilsted, L., ... Jensen, J-U. S. (2022). Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases. BMJ Open Respiratory Research, 9(1). https://doi.org/10.1136/bmjresp-2022-001268

Vancouver

Harboe ZB, Hamm SR, Pérez-Alós L, Sivapalan P, Priemé H, Wilcke T o.a. Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases. BMJ Open Respiratory Research. 2022;9(1). https://doi.org/10.1136/bmjresp-2022-001268

Author

Harboe, Zitta Barrella ; Hamm, Sebastian Rask ; Pérez-Alós, Laura ; Sivapalan, Pradeesh ; Priemé, Helene ; Wilcke, Torgny ; Kjeldgaard, Peter ; Shaker, Saher ; Svorre Jordan, Alexander ; Møller, Dina Leth ; Heftdal, Line Dam ; Madsen, Johannes Roth ; Bayarri-Olmos, Rafael ; Hansen, Cecilie Bo ; Pries-Heje, Mia Marie ; Hasselbalch, Rasmus Bo ; Fogh, Kamille ; Armenteros, Jose Juan Almagro ; Hilsted, Linda ; Sørensen, Erik ; Lindegaard, Birgitte ; Browatzki, Andrea ; Biering-Sørensen, Tor ; Frikke-Schmidt, Ruth ; Ostrowski, Sisse Rye ; Iversen, Kasper Karmark ; Bundgaard, Henning ; Nielsen, Susanne Dam ; Garred, Peter ; Jensen, Jens-Ulrik Stæhr. / Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases. I: BMJ Open Respiratory Research. 2022 ; Bind 9, Nr. 1.

Bibtex

@article{2799a7bf711148b7b169690595caf295,

title = "Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases",

abstract = "INTRODUCTION: Responses to COVID-19 vaccination in patients with chronic pulmonary diseases are poorly characterised. We aimed to describe humoral responses following two doses of BNT162b2 mRNA COVID-19 vaccine and identify risk factors for impaired responses.METHODS: Prospective cohort study including adults with chronic pulmonary diseases and healthcare personnel as controls (1:1). Blood was sampled at inclusion, 3 weeks, 2 and 6 months after first vaccination. We reported antibody concentrations as geometric means with 95% CI of receptor binding domain (RBD)-IgG and neutralising antibody index of inhibition of ACE-2/RBD interaction (%). A low responder was defined as neutralising index in the lowest quartile (primary outcome) or RBD-IgG <225 AU/mL plus neutralising index <25% (secondary outcome), measured at 2 months. We tested associations using Poisson regression.RESULTS: We included 593 patients and 593 controls, 75% of all had neutralising index ≥97% at 2 months. For the primary outcome, 34.7% of patients (n=157/453) and 12.9% of controls (n=46/359) were low responders (p<0.0001). For the secondary outcome, 8.6% of patients (n=39/453) and 1.4% of controls (n=5/359) were low responders (p<0.001). Risk factors associated with low responder included increasing age (per decade, adjusted risk ratio (aRR) 1.17, 95% CI 1.03 to 1.32), Charlson Comorbidity Index (per point) (aRR 1.15, 95% CI 1.05 to 1.26), use of prednisolone (aRR 2.08, 95% CI 1.55 to 2.77) and other immunosuppressives (aRR 2.21, 95% CI 1.65 to 2.97).DISCUSSION: Patients with chronic pulmonary diseases established functional humoral responses to vaccination, however lower than controls. Age, comorbidities and immunosuppression were associated with poor immunological responses.",

keywords = "Adult, Antibody Formation, BNT162 Vaccine, COVID-19/prevention & control, COVID-19 Vaccines, Humans, Immunoglobulin G, Lung Diseases, Prospective Studies, Risk Factors, Vaccination",

author = "Harboe, {Zitta Barrella} and Hamm, {Sebastian Rask} and Laura P{\'e}rez-Al{\'o}s and Pradeesh Sivapalan and Helene Priem{\'e} and Torgny Wilcke and Peter Kjeldgaard and Saher Shaker and {Svorre Jordan}, Alexander and M{\o}ller, {Dina Leth} and Heftdal, {Line Dam} and Madsen, {Johannes Roth} and Rafael Bayarri-Olmos and Hansen, {Cecilie Bo} and Pries-Heje, {Mia Marie} and Hasselbalch, {Rasmus Bo} and Kamille Fogh and Armenteros, {Jose Juan Almagro} and Linda Hilsted and Erik S{\o}rensen and Birgitte Lindegaard and Andrea Browatzki and Tor Biering-S{\o}rensen and Ruth Frikke-Schmidt and Ostrowski, {Sisse Rye} and Iversen, {Kasper Karmark} and Henning Bundgaard and Nielsen, {Susanne Dam} and Peter Garred and Jensen, {Jens-Ulrik St{\ae}hr}",

note = "{\textcopyright} Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",

year = "2022",

doi = "10.1136/bmjresp-2022-001268",

language = "English",

volume = "9",

journal = "B M J Open Respiratory Research",

issn = "2052-4439",

publisher = "B M J Group",

number = "1",

}

RIS

TY - JOUR

T1 - Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases

AU - Harboe, Zitta Barrella

AU - Hamm, Sebastian Rask

AU - Pérez-Alós, Laura

AU - Sivapalan, Pradeesh

AU - Priemé, Helene

AU - Wilcke, Torgny

AU - Kjeldgaard, Peter

AU - Shaker, Saher

AU - Svorre Jordan, Alexander

AU - Møller, Dina Leth

AU - Heftdal, Line Dam

AU - Madsen, Johannes Roth

AU - Bayarri-Olmos, Rafael

AU - Hansen, Cecilie Bo

AU - Pries-Heje, Mia Marie

AU - Hasselbalch, Rasmus Bo

AU - Fogh, Kamille

AU - Armenteros, Jose Juan Almagro

AU - Hilsted, Linda

AU - Sørensen, Erik

AU - Lindegaard, Birgitte

AU - Browatzki, Andrea

AU - Biering-Sørensen, Tor

AU - Frikke-Schmidt, Ruth

AU - Ostrowski, Sisse Rye

AU - Iversen, Kasper Karmark

AU - Bundgaard, Henning

AU - Nielsen, Susanne Dam

AU - Garred, Peter

AU - Jensen, Jens-Ulrik Stæhr

PY - 2022

Y1 - 2022

N2 - INTRODUCTION: Responses to COVID-19 vaccination in patients with chronic pulmonary diseases are poorly characterised. We aimed to describe humoral responses following two doses of BNT162b2 mRNA COVID-19 vaccine and identify risk factors for impaired responses.METHODS: Prospective cohort study including adults with chronic pulmonary diseases and healthcare personnel as controls (1:1). Blood was sampled at inclusion, 3 weeks, 2 and 6 months after first vaccination. We reported antibody concentrations as geometric means with 95% CI of receptor binding domain (RBD)-IgG and neutralising antibody index of inhibition of ACE-2/RBD interaction (%). A low responder was defined as neutralising index in the lowest quartile (primary outcome) or RBD-IgG <225 AU/mL plus neutralising index <25% (secondary outcome), measured at 2 months. We tested associations using Poisson regression.RESULTS: We included 593 patients and 593 controls, 75% of all had neutralising index ≥97% at 2 months. For the primary outcome, 34.7% of patients (n=157/453) and 12.9% of controls (n=46/359) were low responders (p<0.0001). For the secondary outcome, 8.6% of patients (n=39/453) and 1.4% of controls (n=5/359) were low responders (p<0.001). Risk factors associated with low responder included increasing age (per decade, adjusted risk ratio (aRR) 1.17, 95% CI 1.03 to 1.32), Charlson Comorbidity Index (per point) (aRR 1.15, 95% CI 1.05 to 1.26), use of prednisolone (aRR 2.08, 95% CI 1.55 to 2.77) and other immunosuppressives (aRR 2.21, 95% CI 1.65 to 2.97).DISCUSSION: Patients with chronic pulmonary diseases established functional humoral responses to vaccination, however lower than controls. Age, comorbidities and immunosuppression were associated with poor immunological responses.

AB - INTRODUCTION: Responses to COVID-19 vaccination in patients with chronic pulmonary diseases are poorly characterised. We aimed to describe humoral responses following two doses of BNT162b2 mRNA COVID-19 vaccine and identify risk factors for impaired responses.METHODS: Prospective cohort study including adults with chronic pulmonary diseases and healthcare personnel as controls (1:1). Blood was sampled at inclusion, 3 weeks, 2 and 6 months after first vaccination. We reported antibody concentrations as geometric means with 95% CI of receptor binding domain (RBD)-IgG and neutralising antibody index of inhibition of ACE-2/RBD interaction (%). A low responder was defined as neutralising index in the lowest quartile (primary outcome) or RBD-IgG <225 AU/mL plus neutralising index <25% (secondary outcome), measured at 2 months. We tested associations using Poisson regression.RESULTS: We included 593 patients and 593 controls, 75% of all had neutralising index ≥97% at 2 months. For the primary outcome, 34.7% of patients (n=157/453) and 12.9% of controls (n=46/359) were low responders (p<0.0001). For the secondary outcome, 8.6% of patients (n=39/453) and 1.4% of controls (n=5/359) were low responders (p<0.001). Risk factors associated with low responder included increasing age (per decade, adjusted risk ratio (aRR) 1.17, 95% CI 1.03 to 1.32), Charlson Comorbidity Index (per point) (aRR 1.15, 95% CI 1.05 to 1.26), use of prednisolone (aRR 2.08, 95% CI 1.55 to 2.77) and other immunosuppressives (aRR 2.21, 95% CI 1.65 to 2.97).DISCUSSION: Patients with chronic pulmonary diseases established functional humoral responses to vaccination, however lower than controls. Age, comorbidities and immunosuppression were associated with poor immunological responses.

KW - Adult

KW - Antibody Formation

KW - BNT162 Vaccine

KW - COVID-19/prevention & control

KW - COVID-19 Vaccines

KW - Humans

KW - Immunoglobulin G

KW - Lung Diseases

KW - Prospective Studies

KW - Risk Factors

KW - Vaccination

U2 - 10.1136/bmjresp-2022-001268

DO - 10.1136/bmjresp-2022-001268

M3 - Journal article

C2 - 35793836

VL - 9

JO - B M J Open Respiratory Research

JF - B M J Open Respiratory Research

SN - 2052-4439

IS - 1

ER -

ID: 313869899